Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Onconetix, Inc. Common Stock

ONCO

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Last trade $2.97
Day change +$0.06 (+2.06%)
Day range $2.86 – $3.04
Volume 24,401
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.95M
Price / earnings
—
Price / book
0.14×
Price / sales
3.02×
EV / sales
-5.95×
EV / EBITDA
0.5×

Profitability

Earnings per share
-$15.22
Return on assets
-62.07%
Return on equity
-75.69%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.01×
Current ratio
2.21×
Quick ratio
2.14×
Cash ratio
2.02×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$10.31M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ONCO, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$17.12K$21.46K$303.6K$303.65K$106.49K$101.63K$711.98K$406.86K
Cost of revenue$12.82K$23.11K$55.91K$34.76K$35.99K$55.8K$52.01K$301.45K
Gross profit$4.3K-$1.66K$247.68K$268.89K$70.5K$45.83K$659.97K$105.41K
Selling, general and administrative$2.25M$2.04M$1.5M$2.34M$1.52M$1.67M$2.63M$2.64M
Research and development$3.44K$50.82K$24.29K-$3.21K-$111.67K$24.46K-$290$109.37K
Total operating expenses$2.74M$10.22M$1.53M$2.34M$2.01M$12.62M$29.81M$2.75M
Operating income-$2.73M-$10.23M-$1.28M-$2.07M-$1.94M-$12.57M-$29.15M-$2.65M
Interest expense-$4.39K-$2.24K-$4.25K-$300.07K-$223.1K-$223.59K-$248.35K-$384.96K
Income before taxes-$2.87M-$4.21M$5.67M-$8.78M-$2.37M-$8.55M-$30.36M-$3.88M
Income taxes$0$0$525$0$0$0-$918K-$56.38K
Net income-$2.87M-$4.21M$5.67M-$8.78M-$2.37M-$8.55M-$29.44M-$3.83M
Net income attributable to common shareholders-$2.87M-$4.21M$5.67M-$8.78M-$2.7M-$9.72M-$29.64M-$3.83M
EBITDA-$2.24M-$2.09M-$1.28M-$2.07M-$1.34M-$1.65M-$1.85M-$2.44M
Basic earnings per share-$12.80-$671.00$1,812.72-$3,125.00-$2,379.10-$22,725.00-$147,053.19-$124,540.00
Diluted earnings per share-$12.80-$671.00$1,812.72-$3,125.00-$2,379.10-$22,725.00-$147,053.19-$124,540.00

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation

Onconetix announced that Realbotix, its pending acquisition target, has partnered with Bloom Procurement Services to launch a pilot program deploying socially assistive humanoid robots in UK care settings to address loneliness among elderly residents. Realbotix has been accredited as a supplier on Bloom's public sector marketplace. The acquisition is expected to close in the second half of 2026, subject to shareholder approval and regulatory clearances.

Benzinga

Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?

Onconetix Inc. (NASDAQ:ONCO) shares surged 23.65% to $0.38 in after-hours trading on Monday, reversing an 18.26% regular session decline. The biotech company reported clinical validation progress for Proclarix, a blood test for prostate cancer detection, with new peer-reviewed publications and initiation of a U.S. validation trial with Labcorp. However, the stock has dropped 99.11% over the past 12 months and currently trades at its annual low.

Benzinga

What's Going On With Onconetix Shares On Friday?

Onconetix shares surged 71.74% in premarket trading on Friday following the announcement of its acquisition of Realbotix, a company specializing in AI-driven humanoid robots. The acquisition is expected to enhance Onconetix's capabilities in AI and robotics. Additionally, the company implemented a 1-for-5 reverse stock split effective March 25. Despite the positive premarket movement, the stock remains down 92.97% over the past 12 months and trades near its 52-week low.

Benzinga

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

Onconetix and Ocuvex Therapeutics have signed a definitive merger agreement where Onconetix will acquire Ocuvex, with Ocuvex shareholders receiving 90% of the combined company's equity. The transaction is expected to close in Q4 and aims to bring ophthalmic therapeutic assets to the public markets.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 6, 20261-for-10reverse split
May 21, 20261-for-10reverse split
Mar 25, 20261-for-5reverse split
Jun 13, 20251-for-85reverse split
Sep 24, 20241-for-40reverse split
Sep 28, 20161-for-1,500reverse split
May 23, 20061-for-1,000reverse split